Drug Trial Radar · NCT01507831
Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term)
Last checked: Nov 20, 2026Latest source record: Dec 22, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,341
Actual
Start
Jan 2012
Primary completion
Nov 2014
Study completion Nov 2014
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Jan 11, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9). Primary Objective of the study: To evaluate the long-term safety and tolerability of alirocumab in high cardiovascular risk participants with hypercholesterolemia not adequately controlled with their current lipid modifying therapy (LMT). Secondary Objectives: * To evaluate the effect of alirocumab on low-density lipoprotein cholesterol (LDL-C) levels after 24 weeks of treatment in comparison with placebo. * To evaluate the effect of alirocumab in comparison with placebo on LDL-C at other time points. * To evaluate the effects of alirocumab on other lipid parameters.
Conditions
- Hypercholesterolemia
Interventions
Placebo (for alirocumab)Drug
Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
AlirocumabDrug
Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
Lipid-Modifying Therapy (LMT)Drug
Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Experienced Adverse Events (AEs)Time frame: Up to 10 weeks after last study drug administration (maximum of 86 weeks)
Locations
320 sites in 27 countries. Site status is shown where the registry gives one.
Investigational Site Number 840159
Huntsville, Alabama
Investigational Site Number 840028
Gilbert, Arizona
Investigational Site Number 840035
Sierra Vista, Arizona
Investigational Site Number 840052
Tempe, Arizona
Investigational Site Number 840065
Tempe, Arizona
Investigational Site Number 840079
Tempe, Arizona
Investigational Site Number 840094
Tempe, Arizona
Investigational Site Number 840103
Tucson, Arizona
Investigational Site Number 840209
Beverly Hills, California
Investigational Site Number 840194
Beverly Hills, California
Investigational Site Number 840207
Fresno, California
Investigational Site Number 840101
Lincoln, California
Investigational Site Number 840076
Long Beach, California
Investigational Site Number 840214
Pasadena, California
Investigational Site Number 840045
Sacramento, California
Investigational Site Number 840163
Santa Rosa, California
Investigational Site Number 840086
Colorado Springs, Colorado
Investigational Site Number 840077
Golden, Colorado
Investigational Site Number 840224
Bridgeport, Connecticut
Investigational Site Number 840134
Guilford, Connecticut
Investigational Site Number 840246
Hartford, Connecticut
Investigational Site Number 840055
Stamford, Connecticut
Investigational Site Number 840091
Stamford, Connecticut
Investigational Site Number 840150
Atlantis, Florida
Investigational Site Number 840020
Bradenton, Florida
Investigational Site Number 840041
Brandon, Florida
Investigational Site Number 840184
Clearwater, Florida
Investigational Site Number 840242
Clearwater, Florida
Investigational Site Number 840039
Clearwater, Florida
Investigational Site Number 840182
Crystal River, Florida
Investigational Site Number 840002
Daytona Beach, Florida
Investigational Site Number 840166
Daytona Beach, Florida
Investigational Site Number 840167
Fleming Island, Florida
Investigational Site Number 840090
Fort Lauderdale, Florida
Investigational Site Number 840018
Fort Lauderdale, Florida
Investigational Site Number 840153
Jacksonville, Florida
Investigational Site Number 840181
Jacksonville, Florida
Investigational Site Number 840152
Jacksonville, Florida
Investigational Site Number 840154
Lake Mary, Florida
Investigational Site Number 840059
Largo, Florida
Showing 40 of 320 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.